MorphoSys AG — Regulatory Filings 2002

Nov 11, 2002

News Details

Corporate | 11 November 2002 07:30

MorphoSys AG english

MorphoSys Announces Milestone Achievement in Centocor Collaboration Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– MorphoSys AG (Neuer Markt: MOR), the Munich biotechnology company, today announced the successful installation of MorphoSys’ fully automated antibody generation system, AutoCAL, at Centocor’s research facility in Pennsylvania, USA. AutoCAL is a robotic system developed by MorphoSys for the high throughput screening of MorphoSys’ HuCAL antibody libraries. For the successful completion of the AutoCAL test run at Centocor, MorphoSys received a milestone payment. Financial details were not disclosed. MorphoSys and Centocor, a member of the Johnson & Johnson family of companies, signed an expansion of the two companies existing antibody agreement in March 2002. Under the expanded agreement, Centocor increased its funded research at MorphoSys and also ordered AutoCAL, the MorphoSys-developed system for automated screening of antibodies, for use in Centocor’s research programs. Today’s milestone represents the successful completion of the AutoCAL project under the revised agreement, and marks the 2nd milestone reached in the Centocor collaboration to-date. “We are very pleased by the continuing progress of our partnership with Centocor,” said Dr. Thomas von Rüden, Chief Scientific Officer, MorphoSys AG. “Our comprehensive program of antibody technologies, which includes HuCAL GOLD, HuCAL EST and AutoCAL, provides MorphoSys and its collaborators with state-of- the-art tools for creating antibodies for the use in research and as therapeutics.” end of message, (c)DGAP 11.11.2002 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 110730 Nov 02